Search - tctmd.com

Displaying 1 - 20 of 67

Sort: Relevancy | Date

News Daily News

Not Following NOAC Dosing Instructions Tied to Worse Clinical Outcomes

December 12, 2016

News Daily News

Patients With A-fib Still Have High Mortality Risk After Appropriate Anticoagulation Is Started

December 05, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2016

November 30, 2016

News Daily News

Tricky Population of Patients With A-fib Undergoing PCI Tackled in New Consensus Document

November 29, 2016

News Conference News AHA 2016

My Takeaways From AHA 2016: Too Late, Too Soon—Time Waits for No Trial

November 28, 2016

News Daily News

Avoid Simvastatin, Lovastatin in Dabigatran-Treated Patients, Analysis Suggests

November 24, 2016

News Conference News AHA 2016

误诊 NOAC 在日常实践中很常见，并对中风和出血有影响

November 21, 2016

News Conference News AHA 2016

Misdosing NOACs Common in Everyday Practice, With Implications for Stroke and Bleeding

November 21, 2016

News Conference News AHA 2016

Errar la Dosis de NOAC en la Práctica Clínica Diaria es algo Habitual, lo cual tiene Implicaciones en Materia de ACV y Hemorragias

November 21, 2016

News Conference News AHA 2016

Dabigatran Reversal Agent’s Safety, Efficacy Affirmed With Updated Study Results

November 15, 2016

News Conference News AHA 2016

Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI

November 14, 2016

Pivotal Trial Design Considerations: Noninferiority vs Superiority, Device, Control Arm Anticoagulation Durations, NOAC Considerations and More – Industry and Clinician Perspectives

Presentation TCT 2016

Pivotal Trial Design Considerations: Noninferiority vs Superiority, Device, Control Arm Anticoagulation Durations, NOAC Considerations and More Industry and Clinician Perspectives

Presenter: Aaron V. Kaplan, Rachel Neubrander, Brian K. Whisenant

November 01, 2016

Presentation TCT 2016

Debate: Is Left Atrial Appendage Closure Underutilized? No, NOACs Have the Best Efficacy and Safety Profile for Most Patients!

Presenter: Andreas Baumbach, David Hildick-Smith, Jai-Wun Park

November 01, 2016

TCT 53: Thromboembolic Event Rate Is Elevated With Lower Adherence to Warfarin and NOACs

Presentation TCT 2016

TCT 53: Thromboembolic Event Rate Is Elevated With Lower Adherence to Warfarin and NOACs

Presenter: Neal S. Kleiman, David F. Kong, Jeffrey R Winterfield

October 31, 2016

Debate #2: Is LAA Closure Preferred First-line Treatment in Patients With Recent Stents or ACS? No – A Combination of Antiplatelet Agents and Warfarin/NOACs Shoud Be Tried First!

Presentation TCT 2016

Debate #2: Is LAA Closure Preferred First-line Treatment in Patients With Recent Stents or ACS? No A Combination of Antiplatelet Agents and Warfarin/NOACs Shoud Be Tried First!

Presenter: David R. Holmes Jr., Josep Rodés-Cabau, Freek W.A. Verheugt

October 30, 2016

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

Presentation TCT 2016

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

Presenter: Vivek Y. Reddy, Steven J. Yakubov

October 30, 2016

What are Valid Absolute and Relative Contraindications to Warfarin and NOACs?

Presentation TCT 2016

What are Valid Absolute and Relative Contraindications to Warfarin and NOACs?

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt

October 30, 2016

Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance

Presentation TCT 2016

Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Michelle O'Donoghue

October 30, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2016

October 29, 2016

News Daily News

Oral Anticoagulation Use Common in PCI Patients, With Triple Therapy the Norm at Discharge

October 18, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.